Apr 28, 2025 · 40m · capital-allocators
Rodrigo Bitar – Overlooked Opportunities in Latin America (EP.442)
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Ted Seides interviews Rodrigo Bitar, co-founder of 3x1 Partners, to explore contrarian private equity opportunities across overlooked Latin American markets, including Venezuela and Central America. Bitar details their operational playbook for rolling up branded generic pharmaceutical platforms, partnering with family enterprises, and mitigating illiquidity risk through high cash dividend yields.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Ted holds 28.3% of the talking time here. How this is scored →
Ted as informed peer 2.6 Guest teaching 3.8 Guest disagreement 0.4 Ted pushing back 0.3
speaking balance: gold is Ted, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 25:40 Critiquing US energy sanctions policy
Rodrigo openly challenges the logic of recent US oil sanctions policy, pointing out that restricting Venezuelan oil exports to the US achieves the exact opposite of intended geopolitical goals by pushing crude straight to China.
Hardest push from Ted ▶ 27:01 Challenging the feasibility of bargain buyingTed directly pushes back on Rodrigo's claims of dirt-cheap acquisition multiples, asking how realistic it actually is to persuade entrenched private family business owners to sell at steep discounts.
Biggest teaching moment ▶ 17:15 Demystifying Latin American pharma economicsRodrigo educates Ted on the fundamental structure of the Latin American pharmaceutical market, clarifying that it functions as a high-margin branded consumer goods business rather than clinical R&D.
Ted holds their own ▶ 4:25 Synthesizing regional macro themesTed demonstrates deep allocator-level domain context by seamlessly integrating macroeconomic perspectives from James Aitken and Louis-Vincent Gave to frame the broader Latin American investment thesis.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Ted as informed peer | Guest teaching | Guest disagreement | Ted pushing back | Why |
|---|---|---|---|---|---|---|
| Latin American Macro Context and Membership Gift Promotion | 0 | 0 | 0 | 0 | Ted opens the episode with introductory context connecting previous guests' macro theses to Latin America, followed by an internal membership promotion monologue. | |
| The Macro and Geopolitical Case for Latin America | 3 | 3 | 1 | 1 | Ted prompts Rodrigo on Latin America's economic position and shifting geopolitical trade dynamics. Rodrigo details how US nearshoring and free trade agreements insulate the region from global tariff disputes. | |
| Navigating Asymmetric Risk and Opportunity in Venezuela | 3 | 4 | 1 | 1 | Ted questions how Venezuela can present an opportunity given its severe political misalignment with the US. Rodrigo explains the asymmetric risk-reward profile, showing how local oil recovery and overlooked market conditions created steep discounts. | |
| Executing Private Equity Roll-Ups in Venezuelan Pharma | 2 | 4 | 0 | 0 | Ted asks for specific operational examples, and Rodrigo walks through applying the standard US private equity roll-up playbook to consolidate fragmented Venezuelan pharmaceuticals into a market leader. | |
| Sourcing Family Enterprise Partners and Structuring Growth | 3 | 4 | 0 | 0 | Ted asks about sourcing family business partners and post-deal alignment. Rodrigo outlines the extensive multi-year relationship building required to convince multi-generational family owners to accept growth equity. | |
| The Economics and Distribution of Branded Generics | 2 | 5 | 1 | 0 | Rodrigo reframes Ted's question by explaining that Latin American pharma operates as branded consumer generics with 30-35% cash margins and doctor marketing rather than high-risk US-style R&D drug discovery. | |
| Valuation Multiples, Capital Scarcity, and Add-On Acquisitions | 3 | 4 | 0 | 0 | Ted presses on entry valuations and pricing negotiations. Rodrigo shares concrete transaction metrics, citing sub-4x EBITDA purchases including acquiring distressed local assets from multinational players like Pfizer. | |
| Sponsor Message: Ridgeline Unified Investment Technology Platform | 2 | 3 | 0 | 0 | Following a sponsor break, Ted checks in on exit timing and operational performance, with Rodrigo discussing dividend cash generation while awaiting normalized regional buyer demand. | |
| Macro Surprises: Dollarization and Evolving US Energy Policy | 3 | 5 | 1 | 1 | Ted inquires about unexpected macro headwinds. Rodrigo contrasts the rapid de facto dollarization of the Venezuelan economy with counterintuitive shifts in US oil sanctions that inadvertently routed crude to China. | |
| Negotiating Family Deals and Regional Portfolio Diversification | 3 | 4 | 0 | 0 | Ted asks how easy it is to negotiate low valuation multiples from reluctant owners. Rodrigo explains how providing operational liquidity and cross-border integration creates mutual upside for entrenched family founders. | |
| Applying the Private Equity Playbook Across Central America | 3 | 5 | 0 | 0 | Rodrigo details replicating their Venezuelan playbook in Central America, purchasing regional pharma platforms at 7-8x EBITDA to roll up fragmented markets for eventual 10-14x exits. | |
| Managing Fund Mandates and Illiquidity in Emerging Markets | 4 | 4 | 1 | 1 | Ted pushes on fund structural constraints and LP reception to high-risk emerging markets. Rodrigo discusses managing illiquidity through high asset yield and notes shifting allocator sentiment from outright dismissal to selective interest. |
Statements from this episode (19)
Bitar: U.S. tariffs will have minimal impact on Latin America
“So the impact, if you look around the world, which are the regions who are going to be more impacted, Latin America falls under the category of minimal impact.”
Bitar: Venezuelan oil production has rebounded to one million barrels daily
“We have seen growth in that oil production up to a million barrels of oil.”
Bitar: 3x1 Partners' portfolio grew 40% annually over four years
“Our portfolio has grown about 40% per annum the last four years”
Bitar: Perceived investment risk in Venezuela substantially exceeds actual risk
“It was a situation where there was a perceived risk much greater than the real risk, in our view, and a country that was overlooked by investors for understandable reasons, and that created an opportunity where you could find very High quality assets at very a…”
Bitar: 3x1 grew a Venezuelan pharma asset from #6 to #2
“So we followed that playbook and we began acquiring a company that was the number six in the market. And in the span of a little bit less than three years, it's become the number two pharmaceutical manufacturer. So that's meant about a tripling or quadrupling …”
Bitar: Latin American family owners rarely sell foundational trophy assets
“In most of the economies in Latin America where you go, these are like trophy assets that whomever the owner is, normally families, they don't want to trade it. Having the ability to go into a market which is a little bit overlooked or an empty room, as you sa…”
Bitar: Latin American branded generics deliver 30% to 35% margins
“Still, they're very profitable, 30 to 35% margins, little capex, so they generally, they generate a lot of cash flow, which is also very relevant to us.”
Bitar: Venezuelan pharmaceutical market grew 20% to 30% annually
“Health is one of the priorities, and the rate of growth of that market has been 20, 30% per annum for the past three, four years in Venezuela.”
Bitar: Venezuelan acquisition entry valuations are currently sub-4x EBITDA
“Now the valuations are sub four times EBITDA.”
Bitar: 3x1 acquired Pfizer's Venezuelan assets at ~3.5x to 4x EBITDA
“And then we subsequently acquired the assets of Pfizer in Venezuela. And then we subsequently last year acquired local assets Of a company called Vivas Pharmaceuticals, and the multiples were all around there.”
Bitar: Strategic foreign exits for Venezuelan assets remain a long-term prospect
“For Venezuelan assets, what we believe is the necessary condition for exits is that it becomes a geography where foreign investors are willing to come back in and acquire these strategic assets. What we're looking to do Build those strategic assets in anticipa…”
Bitar: All Venezuelan asset pricing has become effectively dollarized
“Within the scope of a year until today, in fact, all of the pricing of all of the assets is dollarized. They may not be listed in dollars, but the underlying amount for pricing everything is in dollars.”
Bitar: U.S. restrictions on Venezuelan oil push exports to China
“In the last month or two, there's been a shift in that, more towards restriction of the sale of Venezuelan oil to the U.S., In practice, what it's doing is pushing it to China, which is odd, because that would seem counter to the U.S. Objectives.”
Bitar: U.S. refining infrastructure ensures long-term Venezuelan oil ties
“Nevertheless, we believe that because of the refining infrastructure in the southern U.S., which is, you know, has been built for Venezuelan crude, that's a natural relationship that should endure in the future, but there's many geopolitical things that are sh…”
Bitar: Central American healthcare is growing 10% to 15% annually
“Healthcare is growing like 10 to 15% growth annually, which is very attractive to us.”
Bitar: Latin American regional platforms command 10x to 14x EBITDA
“When you look at the latest transactions in the past five, six years in Latin America, all these regional guys have gone from like 10 to 14 times EBITDA. And the going in price for these assets is like seven to eight times EBITDA.”
Bitar: Latin America will align with the U.S. in multipolar world
“And I think, again, like we said at the beginning, this multipolar world, Latin America will certainly be together with the U.S., and that will mean further growth, integration, opportunities.”